NCI HPV Trial Data Re-Evaluated By Digene To Support PMA Supplement
This article was originally published in The Gray Sheet
Executive Summary
Digene will reanalyze clinical data and specimens from a 23,702-patient trial in Portland, Oregon, prior to seeking a primary screening indication for its HybridCapture 2 HPV test. The Gaithersburg, Maryland firm expects to file a PMA supplement by year-end.
You may also be interested in...
Digene DNA Pap Test Cost-Benefit Studies Set Stage For Reimbursement
Recent studies evaluating the cost-effectiveness of Digene's DNA Pap test for cervical cancer may help support reimbursement for a primary screening indication pending FDA approval, the firm says
Digene DNA Pap Test Cost-Benefit Studies Set Stage For Reimbursement
Recent studies evaluating the cost-effectiveness of Digene's DNA Pap test for cervical cancer may help support reimbursement for a primary screening indication pending FDA approval, the firm says
Digene/Cytyc Product Supplier Snatched Up By Cooper Unit In $12 Mil. Deal
Cooper Surgical's purchase of Digene supplier Medscand Medical poises Cooper to benefit from the HPV test manufacturer's pursuit of a primary screening indication for the Hybrid Capture 2 (HC2).